Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

10.1K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
10.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.3K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.8K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates.

Blood neoplasia·2026
Same author

System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced Cost.

Transplantation and cellular therapy·2026
Same author

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Blood·2026
Same author

Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102).

JCO oncology advances·2026
Same author

TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Mar 10, 2026

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets
09:09

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets

Published on: April 18, 2016

16.0K

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.

Shane A Curran1, Justin A Shyer1, Erin T St Angelo1

  • 1Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.

Cancer Immunology Research
|December 8, 2016
PubMed
Summary

Selective JAK2 inhibitors preserve natural killer (NK) cell function, unlike less selective JAK inhibitors that impair NK cells. This highlights the potential of specific JAK2 inhibition in immunotherapy and preventing transplant complications.

More Related Videos

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

21.4K
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

11.3K

Related Experiment Videos

Last Updated: Mar 10, 2026

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets
09:09

An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets

Published on: April 18, 2016

16.0K
Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

21.4K
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

11.3K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Janus kinase (JAK) inhibitors show promise in myeloproliferative neoplasms but can reduce natural killer (NK) cell function.
  • The precise impact of JAK inhibitors on NK cells and the underlying mechanisms are not fully understood.
  • Selective JAK2 inhibition is being explored for graft-versus-host disease prevention post-transplantation.

Purpose of the Study:

  • To compare the effects of a selective JAK2 inhibitor (TG101348) versus a less selective JAK1/2 inhibitor (ruxolitinib) on human NK-cell activation and function.
  • To elucidate the mechanisms by which JAK inhibitors affect NK-cell responses, particularly STAT5 phosphorylation.
  • To assess the impact of different dendritic cell (DC) subtypes on NK-cell responses under JAK inhibition.

Main Methods:

  • Treatment of NK cells with common γc cytokines and co-culture with monocyte-derived dendritic cell (moDC) subtypes.
  • Application of selective JAK2 inhibitor (TG101348) and less selective JAK1/2 inhibitor (ruxolitinib).
  • Assessment of NK-cell activation markers, cytokine secretion (IFNγ), cytotoxicity, proliferation, and STAT5 phosphorylation (pSTAT5).

Main Results:

  • Ruxolitinib completely abrogated IL-2, IL-15, and DC-mediated NK-cell STAT5 phosphorylation, IFNγ secretion, and cytotoxicity.
  • NK-cell proliferation stimulated by moDCs was the only function resistant to ruxolitinib.
  • TG101348 caused less functional impairment, with complete inhibition only of soluble IL-15-mediated STAT5 phosphorylation, which could be rescued by Langerhans-type DCs presenting membrane-bound IL-15.
  • Ruxolitinib's broad JAK inhibition led to profound NK-cell dysfunction via pSTAT5 blockade.

Conclusions:

  • Nonselective JAK1/2 inhibition by ruxolitinib significantly compromises NK-cell function by blocking pSTAT5.
  • Selective JAK2 inhibition, as demonstrated by TG101348, preserves NK-cell function more effectively.
  • Selective JAK2 inhibitors offer a promising therapeutic strategy for immunotherapeutic applications, potentially avoiding NK-cell related side effects seen with broader JAK inhibitors.